Coronavirus structure, illustration

Coronavirus: What We Know Today and Where Do We Go from Here

Illumina’s Staff Product Manager of Infectious Disease Michael Oberholzer, Ph.D., and Chief Medical Officer Phil Febbo, M.D., offer their perspective on the novel Coronavirus SARS-CoV-2 (2019-nCoV) outbreak.
Delicious Mediterranean Appetizer from directly above.

Mediterranean Diet Improves Gut Microbiome, Promotes Healthy Aging

A five-country study found that eating a Mediterranean diet for a year boosts the types of gut bacteria linked to “healthy” aging while reducing those associated with harmful inflammation in the elderly.

Triple negative breast cancer might not actually be ‘breast cancer’

The study could signal a potential treatment breakthrough for patients with this form of breast cancer, which disproportionately affects and tends to develop more aggressively in black women.
Unrecognizable businessman having chest pain and heart attack

PRS Only Marginally Better than Established Methods of Predicting Heart Disease

While the results showed a strong association between polygenic risk scores and CHD, with those scoring highest on this calculator at baseline most likely to experience cardiac events over the follow-up period, the results were roughly the same using the ACC/AHA calculator.

Small Sequencer Developer GenapSys Completes $90M Series C Financing

GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.

Takeda Invests in Patient-Centric Health Data Company Seqster

The investment allows Seqster to ramp up development of its technology which streamlines patient recruitment for clinical trials by matching consenting patients based on their EHR, genomic, and real-time digital data delivered by wearable monitoring devices.
Illustration of amyloid plaques on a nerverticale cell

Researchers Detail Mechanism for Clearing Misfolded Proteins at Root of Alzheimer’s Disease

The chaperone protein Clusterin shuttles misfolded proteins directly into cells for degradation, a finding that could point to new therapeutic targets for AD and other neurodegenerative diseases.
CellMax Life's CMxTM circulating tumor cell (CTC) platform and liquid biopsy panel will be used by Medigen Biotech in upcoming clinical trials of its cell therapy candidates for cancers

New Liquid Biopsy Method IDs Melanoma Patients Likely to Relapse

Although CTCs can be detected in melanoma patients, there is limited data regarding their significance in stage III (node-positive) disease. This prospective study was based on earlier studies that found CTCs in a significant number of breast cancer patients was associated with relapse, independent of other prognostic methods.
Illustration of a cancer cell

Alternative Splicing Identified as a Potential Driver of Aggressive Cancers

The researchers developed new computational tools and biological model systems to study the link between a strong cancer driver gene that impacts changes in proteins related to alternative splicing regulation.
DNA research concept DNA barcodes for biomedical research  mitochondrial DNA  Prostate cancer DNA test

8 Companion Diagnostic Developers Making a Mark

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
DNA Modification

New Method Could Help Geneticists Identify Rare Disease Genes

Dubbed FUSIL (Full Spectrum of Intolerance to Loss-of-function), the open-source database created by EMBL-EBI is intended to help researchers identify rare disease mutations by categorizing which genes are essential for supporting life.
Uterus Cancer

New Study Reveals Dozens of Pathways in Endometrial Cancer Development

This look at endometrial cancer offers insights to better identify which patients will need aggressive treatment and which won't, clues on why certain treatments are not effective with some patients, and suggestions for drugs to target proteins CDK12, SMARCA4, and PML.
Businessman using mobile phone in office hallway

Cell Phone Use and Genetic Variations Linked in Thyroid Cancer Study

Cell phone users with single nucleotide polymorphisms (SNPs) in four of the genes studied were more than two times more likely to develop cancer. Overall, the researchers found 10 SNPs that appear to increase the risk of thyroid cancer among cell phone users.
binary code pattern

The Biomarker Future is Digital

As demand continues to grow for more data to inform precision medicine, digital biomarkers represent a new class of biomarkers that provide information in real time.
Light micrograph of metastases in breast tissue

Triple Negative Breast Cancer Recurrence Prediction Method Developed

Women whose plasma contained circulating tumor DNA had only a 56% chance of being cancer-free two years following chemotherapy and surgery, while those without it had an 81% chance the cancer would not return in the same time span.

Precision Oncology Company OncoDNA Closes $20M Series B Financing

OncoDNA said the financing is designed to support rapid international growth, accelerate software development, and carry out hiring initiatives.

Somatic Mutations at Root of Some Cancers Apparent Years Before Onset

The findings suggest that tumor development can span the entire lifetime of an individual, so the mutations that initiate cancer progression may arise decades before diagnosis.
Autism spectrum disorder, conceptual illustration

102 New Autism Genes Mapped

In this most recent ASC study, researchers mapped the genes of 35,584 individuals, of whom 11,986 had autism, to determine how many times each gene is affected by variants with protein disrupting consequences.
The FDA has approved Roche’s VENTANA PD-L1 (SP142) Assay as the first companion diagnostic authorized for the breast cancer combination therapy of Tecentriq

Detailed Map of Breast Cancer Reveals the Effects of Mutations on the Tumor Landscape

The maps detail the intricacies and complexity of the breast cancer landscape—comprising cancer cells, immune cells and connective tissue—and how it varies both between, and within, tumors depending on their unique genetic makeup.
Internet network

Looking Ahead to 2030

While much progress has been made, it is fair to say more advances are needed before precision medicine and/or genomic medicine is standard practice. So how will we get there? Read on as four industry watchers share with you their thought on what may happen in the next ten years to advance the field.
T cell populations in colorectal tumor tissue.

Engineered Probiotic Can Deliver Immune Checkpoint Inhibiting Nanobodies Directly to Tumors

When tested in cancer-bearing mice, a single dose of the bacteria continuously produced and released the anti-PD-L1 and anti-CTLA-4 nanobodies, triggering an immune response that led to tumor regression. The researchers say the platform could be used to deliver multiple immunotherapies simultaneously, enabling the release of effective therapeutic combinations for hard-to-treat cancers.
CRISPR technology

CRISPR-Edited T Cells Clear First Hurdle in Cancer Clinical Trial

The Phase I clinical trial to evaluate CRISPR-Cas9-edited T cells in humans with advanced cancer, led by immunotherapy pioneer Carl June, has reported the patients experienced no negative side effects, and that the engineered T cells persisted in their bodies for months.
Esophageal cancer, illustration

Lucid Diagnostics’ Esophageal DNA Test Gets FDA Breakthrough Designation

Lucid seeks to improve the diagnosis of Barrett’s Esophagus (BE), with and without dysplasia—a progression of precursor conditions that culminate in highly lethal esophageal cancer (EAC), as well as EAC itself, in patients with gastroesophageal reflux disease (GERD).

Potency Assays for Cell and Gene Therapy

Polygenic risk scores deliver a more precise estimation of individualized risk of developing a disease, with heart disease and cancer leading the way.
Source: freestylephoto/Getty Images

20 Molecular Diagnostics Companies to Watch

Up-and-Coming Diagnostic Test Developers Emerge as Consolidation Thins the Field.
Scroll Up